β cells derived from stem cells improve blood glucose control in patients with diabetes.

Spatial host–microbiome sequencing simultaneously profiles microbes and host transcriptomes from mouse colons.

Interactions among plant hosts, bacteria and fungi are measured at high spatial resolution.

Norepinephrine neurons, a drug target for neurologic diseases, are produced from stem cells.

Long-term expression of AAV transgenes in macaque liver is traced to integrated vectors.

Compressed Perturb-seq incorporates compressed sensing to genetic screening for scalable discovery of genetic interactions.

Nature Biotechnology editors pick their favorite research articles from 2023.

Nature Biotechnology’s annual survey highlights academic start ups that are, among other things, correcting misfolded or disordered proteins, creating second-generation GPCR agonists, building a new gene delivery platform and mining cancer genomes for novel targets.

Our ranking is out, and it has a few surprises. In pole position — predictably — is Wegovy, the weight-slashing GLP-1 agonist, with AI-hallucinated proteins a close second. These are followed by drugging options for RNA. The dark horses are virus-free gene therapies and a sweet protein.

The go-ahead for Vertex’s gene editing therapy in sickle cell disease and β-thalassemia is a historic milestone, but this one-time treatment is costly.